Castelvecchio Pascoli (Lucca) – October 15, 2021 – Kedrion SpA announced today that it has closed on the acquisition of the remainder of the Liminal BioSciences plasma-derived therapeutics business under the terms of the Share Purchase Agreement entered into by the Kedrion S.p.A and Liminal Biosciences (the “Second Closing”).
This acquisition includes the Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) business operated through the subsidiary of Liminal Bioscences, Prometic Biotherapeutics Inc. (“PBT”), holder of the biological license application (“BLA”) for Ryplazim®. With this Second Closing Kedrion will therefore assume all development, manufacturing and commercialization activities and operating costs for Ryplazim® effective as of the closing date.
Plasminogen is a protein synthesized by the liver and circulates in the blood. Activated plasminogen, plasmin, is a fundamental component of the fibrinolytic system and is the main enzyme involved in the lysis of blood clots and clearance of extravasated fibrin. Plasminogen is therefore vital in wound healing, cell migration, tissue remodeling, angiogenesis, and embryogenesis.
Kedrion Biopharma is an international biopharmaceutical company based in Italy that collects and fractionates plasma to produce and distribute worldwide plasma-derived products for the prevention and treatment of rare and debilitating diseases and conditions such as Hemophilia, Primary Immunodeficiencies and Rh sensitization.
Headquartered in Tuscany with more than 2,500 employees worldwide, Kedrion has a commercial presence in 100 countries and is the 5th largest player in the world, and Italy’s 1st.
Kedrion has manufacturing plants in Italy, Hungary and North America, and its subsidiary KEDPLASMA operates plasma collection centers in North America.
Kedrion acts as a bridge between donors and the people who need treatments and works on a global scale to expand patient access to available plasma-derived therapies.